跳转至内容
Merck

SML2624

Sigma-Aldrich

Dexlansoprazole

≥98% (HPLC)

别名:

(R)-(+)-Lansoprazole, (R)-(+)2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C16H14F3N3O2S
分子量:
369.36
MDL號碼:
分類程式碼代碼:
12352200
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

powder

光學活性

[α]/D +142 to +158°, c = 1 in chloroform-d

顏色

white to beige

溶解度

DMSO: 2 mg/mL, clear

儲存溫度

2-8°C

InChI

1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1

InChI 密鑰

MJIHNNLFOKEZEW-RUZDIDTESA-N

生化/生理作用

Dexlansoprazole is a proton pump inhibitor. It is the active enantiomer of lansoprazole used to treat gastroesophageal reflux disease (GERD).

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Karen E Hansen et al.
Gastroenterology, 156(4), 926-934 (2018-11-18)
Epidemiological studies have associated proton pump inhibitor (PPI) therapy with osteoporotic fractures, but it is not clear if PPIs directly cause osteoporosis. We evaluated the effect of dexlansoprazole and esomeprazole on bone turnover, bone mineral density (BMD), true fractional calcium
Khean Lee Goh et al.
Journal of neurogastroenterology and motility, 22(3), 355-366 (2016-03-05)
Although gastroesophageal reflux disease is not as common in Asia as in western countries, the prevalence has increased substantially during the past decade. Gastroesophageal reflux disease is associated with considerable reductions in subjective well-being and work productivity, as well as

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门